In vivo bioluminescence imaging to evaluate systemic and topical antibiotics against community-acquired methicillin-resistant staphylococcus aureus-infected skin wounds in mice

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 2, 2013, Pages 855-863

  Guo, Yi ^a   Ramos, Romela Irene ^b   Cho, John S ^c   Donegan, Niles P ^a   Cheung, Ambrose L ^a   Miller, Lloyd S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLINDAMYCIN; DAPTOMYCIN; DOXYCYCLINE; LINEZOLID; NOVAPLUS; PSEUDOMONIC ACID; RETAPAMULIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL LOAD; BIOLUMINESCENCE; BIOLUMINESCENCE IMAGING; COLONY FORMING UNIT; COMMUNITY ACQUIRED METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; CONTROLLED STUDY; DRUG EFFICACY; IMAGE ANALYSIS; IMAGING; IN VIVO STUDY; INOCULATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; WOUND INFECTION;

ACETAMIDES; ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; BICYCLO COMPOUNDS, HETEROCYCLIC; CLINDAMYCIN; COMMUNITY-ACQUIRED INFECTIONS; DAPTOMYCIN; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DOXYCYCLINE; LUMINESCENT MEASUREMENTS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED C57BL; MUPIROCIN; OXAZOLIDINONES; SKIN; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; VANCOMYCIN; WOUND HEALING;

EID: 84872858088     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01003-12     Document Type: Article

References (62)

1. David MZ, Daum RS. 2010. Community-associated methicillin-resistant Staphylococcus aureus: Epidemiology and clinical consequences of an emerging epidemic. Clin. Microbiol. Rev. 23:616-687.
2. Deleo FR, Otto M, Kreiswirth BN, Chambers HF. 2010. Communityassociated methicillin-resistant Staphylococcus aureus. Lancet 375:1557-1568.
3. McCaig LF, McDonald LC, Mandal S, Jernigan DB. 2006. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg. Infect. Dis. 12:1715-1723.
4. Hersh AL, Chambers HF, Maselli JH, Gonzales R. 2008. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch. Intern. Med. 168:1585-1591.
5. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, Talan DA. 2006. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355:666-674.
6. Talan DA, Krishnadasan A, Gorwitz RJ, Fosheim GE, Limbago B, Albrecht V, Moran GJ. 2011. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin. Infect. Dis. 53:144-149.
7. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. 2006. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA300 clone as the predominant cause of skin and soft-tissue infections. Ann. Intern. Med. 144:309-317.
8. Jones RN, Nilius AM, Akinlade BK, Deshpande LM, Notario GF. 2007. Molecular characterization of Staphylococcus aureus isolates from a 2005 clinical trial of uncomplicated skin and skin structure infections. Antimicrob. Agents Chemother. 51:3381-3384.
9. Tenover FC, Goering RV. 2009. Methicillin-resistant Staphylococcus aureus strain USA300: Origin and epidemiology. J. Antimicrob. Chemother. 64:441-446.
10. Daum RS. 2007. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N. Engl. J. Med. 357:380-390.
11. Elston DM. 2007. Community-acquired methicillin-resistant Staphylococcus aureus. J. Am. Acad. Dermatol. 56:1-16.
12. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak J, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52:e18-e55.
13. Dryden MS. 2010. Complicated skin and soft tissue infection. J. Antimicrob. Chemother. 65(Suppl 3):iii35-iii44.
14. Curcio D. 2011. Skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus: Role of tigecycline. Clin. Infect. Dis. 52:1468-1469.
15. Bode LG, Kluytmans JA, Wertheim HF, Bogaers D, Vandenbroucke-Grauls CM, Roosendaal R, Troelstra A, Box AT, Voss A, d, Tvan IBAvan Verbrugh HA, Vos MC. 2010. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N. Engl. J. Med. 362:9-17.
16. Yang LP, Keam SJ. 2008. Retapamulin: A review of its use in the management of impetigo and other uncomplicated superficial skin infections. Drugs 68:855-873.
17. Hahn BL, Onunkwo CC, Watts CJ, Sohnle PG. 2009. Systemic dissemination and cutaneous damage in a mouse model of staphylococcal skin infections. Microb. Pathog. 47:16-23.
18. Kugelberg E, Norstrom T, Petersen TK, Duvold T, Andersson DI, Hughes D. 2005. Establishment of a superficial skin infection model in mice by using Staphylococcus aureus and Streptococcus pyogenes. Antimicrob. Agents Chemother. 49:3435-3441.
19. Heggers JP, McHugh T, Zoellner S, Boertman JA, Niu XT, Robson MC, Velanovich V. 1989. Therapeutic efficacy of timentin and augmentin versus silvadene in burn wound infections. J. Burn Care Rehabil. 10:421-424.
20. Rode H, de Wet PM, Millar AJ, Cywes S. 1988. Bactericidal efficacy of mupirocin in multi-antibiotic resistant Staphylococcus aureus burn wound infection. J. Antimicrob. Chemother. 21:589-595.
21. Yamakawa T, Mitsuyama J, Hayashi K. 2002. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J. Antimicrob. Chemother. 49:455-465.
22. Boon RJ, Beale AS. 1987. Response of Streptococcus pyogenes to therapy with amoxicillin or amoxicillin-clavulanic acid in a mouse model of mixed infection caused by Staphylococcus aureus and Streptococcus pyogenes. Antimicrob. Agents Chemother. 31:1204-1209.
23. Gisby J, Bryant J. 2000. Efficacy of a new cream formulation of mupirocin: Comparison with oral and topical agents in experimental skin infections. Antimicrob. Agents Chemother. 44:255-260.
24. McRipley RJ, Whitney RR. 1976. Characterization and quantitation of experimental surgical-wound infections used to evaluate topical antibacterial agents. Antimicrob. Agents Chemother. 10:38-44.
25. Rittenhouse S, Singley C, Hoover J, Page R, Payne D. 2006. Use of the surgical wound infection model to determine the efficacious dosing regimen of retapamulin, a novel topical antibiotic. Antimicrob. Agents Chemother. 50:3886-3888.
26. Thurlow LR, Hanke ML, Fritz T, Angle A, Aldrich A, Williams SH, Engebretsen IL, Bayles KW, Horswill AR, Kielian T. 2011. Staphylococcus aureus biofilms prevent macrophage phagocytosis and attenuate inflammation in vivo. J. Immunol. 186:6585-6596.
27. Kadurugamuwa JL, Sin L, Albert E, Yu J, Francis K, DeBoer M, Rubin M, Bellinger-Kawahara C, Parr TRJ, Jr, Contag PR. 2003. Direct con-tinuous method for monitoring biofilm infection in a mouse model. Infect. Immun. 71:882-890.
28. Cho JS, Zussman J, Donegan NP, Ramos RI, Garcia NC, Uslan DZ, Iwakura Y, Simon SI, Cheung AL, Modlin RL, Kim J, Miller LS. 2011. Noninvasive in vivo imaging to evaluate immune responses and antimicrobial therapy against Staphylococcus aureus and USA300 MRSA skin infections. J. Invest. Dermatol. 131:907-915.
29. Fang RC, Kryger ZB, Buck DW, De la Garza M, Galiano RD, Mustoe TA. 2010. Limitations of the db/db mouse in translational wound healing research: Is the NONcNZO10 polygenic mouse model superior? Wound. Repair Regen. 18:605-613.
30. Crandon JL, Kuti JL, Nicolau DP. 2010. Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillinresistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model. Antimicrob. Agents Chemother. 54:5115-5119.
31. Reyes N, Skinner R, Benton BM, Krause KM, Shelton J, Obedencio GP, Hegde SS. 2006. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58:462-465.
32. Dandekar PK, Tessier PR, Williams P, Nightingale CH, Nicolau DP. 2003. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J. Antimicrob. Chemother. 52:405-411.
33. LaPlante KL, Leonard SN, Andes DR, Craig WA, Rybak MJ. 2008. Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprimsulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models. Antimicrob. Agents Chemother. 52:2156-2162.
34. Louie A, Liu W, Kulawy R, Drusano GL. 2011. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob. Agents Chemother. 55:3453-3460.
35. Girard AE, Girard D, Gootz TD, Faiella JA, Cimochowski CR. 1995. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrob. Agents Chemother. 39:2210-2216.
36. Azeh I, Gerber J, Wellmer A, Wellhausen M, Koenig B, Eiffert H, Nau R. 2002. Protein synthesis inhibiting clindamycin improves outcome in a mouse model of Staphylococcus aureus sepsis compared with the cell wall active ceftriaxone. Crit. Care Med. 30:1560-1564.
37. Cadena J, Nair S, Henao-Martinez AF, Jorgensen JH, Patterson JE, Sreeramoju PV. 2011. Dose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 55:5430-5432.
38. Schmitz GR, Bruner D, Pitotti R, Olderog C, Livengood T, Williams J, Huebner K, Lightfoot J, Ritz B, Bates C, Schmitz M, Mete M, Deye G. 2010. Randomized controlled trial of trimethoprim-sulfamethoxazole for uncomplicated skin abscesses in patients at risk for community-associated methicillin- resistant Staphylococcus aureus infection. Ann. Emerg. Med. 56:283-287.
39. Hilliard JJ, Fernandez J, Melton J, Macielag MJ, Goldschmidt R, Bush K, Abbanat D. 2009. In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457. Antimicrob. Agents Chemother. 53:2028-2033.
40. Healy DP, Polk RE, Garson ML, Rock DT, Comstock TJ. 1987. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob. Agents Chemother. 31:393-397.
41. Woodworth J, Nyhart EH, Jr, Brier GL, Wolny JD, Black HR. 1992. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob. Agents Chemother. 36:318-325.
42. Burkhardt O, Borner K, Hnvon der, Koppe P, Pletz MW, Nord CE, Lode H. 2002. Single-and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers. J. Antimicrob. Chemother. 50:707-712.
43. Saano V, Paronen P, Peura P. 1990. Bioavailability of doxycycline from dissolved doxycycline hydrochloride tablets: Comparison to solid form hydrochloride tablets and dissolved monohydrate tablets. Int. J. Clin. Pharmacol. Ther. Toxicol. 28:471-474.
44. Clinical and Laboratory Standards Institute (CLSI). 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. CLSI document M07-A9. CLSI, Wayne, PA.
45. Seaton RA. 2008. Daptomycin: Rationale and role in the management of skin and soft tissue infections. J. Antimicrob. Chemother. 62(Suppl 3): Iii15-iii23.
46. Lipsky BA, Tabak YP, Johannes RS, Vo L, Hyde L, Weigelt JA. 2010. Skin and soft tissue infections in hospitalized patients with diabetes: Culture isolates and risk factors associated with mortality, length of stay and cost. Diabetologia 53:914-923.
47. Dryden MS. 2011. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J. Antimicrob. Chemother. 66(Suppl 4):iv7-iv15.
48. Otto M. 2010. Basis of virulence in community-associated methicillinresistant Staphylococcus aureus. Annu. Rev. Microbiol. 64:143-162.
49. Wang R, Braughton KR, Kretschmer D, Bach TH, Queck SY, Li M, Kennedy AD, Dorward DW, Klebanoff SJ, Peschel A, Deleo FR, Otto M. 2007. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat. Med. 13:1510-1514.
50. Andreu N, Zelmer A, Wiles S. 2011. Noninvasive biophotonic imaging for studies of infectious disease. FEMS Microbiol. Rev. 35:360-394.
51. Hutchens M, Luker GD. 2007. Applications of bioluminescence imaging to the study of infectious diseases. Cell Microbiol. 9:2315-2322.
52. Pribaz JR, Bernthal NM, Billi F, Cho JS, Ramos RI, Guo Y, Cheung AL, Francis KP, Miller LS. 2012. Mouse model of chronic post-arthroplasty infection: Noninvasive in vivo bioluminescence imaging to monitor bacterial burden for long-term study. J. Orthop. Res. 30:335-340.
53. Davis SL, McKinnon PS, Hall LM, Delgado G, Jr, Rose W, Wilson RF, Rybak MJ. 2007. Daptomycin versus vancomycin for complicated skin and skin structure infections: Clinical and economic outcomes. Pharmacotherapy 27:1611-1618.
54. Lipsky BA, Stoutenburgh U. 2005. Daptomycin for treating infected diabetic foot ulcers: Evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J. Antimicrob. Chemother. 55:240-245.
55. McKinnon PS, Sorensen SV, Liu LZ, Itani KM. 2006. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Ann. Pharmacother. 40:1017-1023.
56. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. 2005. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 49:2260-2266.
57. Lipsky BA, Itani KM, Weigelt JA, Joseph W, Paap CM, Reisman A, Myers DE, Huang DB. 2011. The role of diabetes mellitus in the treatment of skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: Results from three randomized controlled trials. Int. J. Infect. Dis. 15:e140-e146.
58. Itani KM, Weigelt J, Li JZ, Duttagupta S. 2005. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents 26:442-448.
59. Itani KM, Dryden MS, Bhattacharyya H, Kunkel MJ, Baruch AM, Weigelt JA. 2010. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am. J. Surg. 199: 804-816.
60. Sharpe JN, Shively EH, Polk HC, Jr. 2005. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am. J. Surg. 189: 425-428.
61. LaPlante KL, Rybak MJ, Amjad M, Kaatz GW. 2007. Antimicrobial susceptibility and staphylococcal chromosomal cassette mec type in community-and hospital-associated methicillin-resistant Staphylococcus aureus. Pharmacotherapy 27:3-10.
62. Tokunaga T, Oka K, Takemoto A, Ohtsubo Y, Gotoh N, Nishino T. 1997. Efficacy of trimethoprim in murine experimental infection with a thymidine kinase-deficient mutant of Escherichia coli. Antimicrob. Agents Chemother. 41:1042-1045.